New research, published in the journal Radiology, suggests some types of a popular contrast agent used in magnetic resonance imaging (MRI) exams may remain in the brain for years, but that the long-term effects are unknown.


Carestream showcased the advanced interoperability of its Clinical Collaboration Platform (CCP) at the IHE-Europe (Integrating the Healthcare Enterprise) Connectathon held April 20-24 in Luxembourg. Carestream announced that the CCP product suite successfully passed all integration tests at the Connectathon including all profiles for its universal viewer, vendor-neutral archive (VNA) and image capture solutions. Carestream is also among the first VNA suppliers to implement HL7's new Fast Healthcare Interoperability Resources (FHIR) framework.

Research firm KLAS released a new report on electronic medical record (EMR) usability and product performance over the past two years, revealing how physicians and other users rate various vendors and solutions. The report, entitled “Physician Leadership Weighs In on Acute Care EMR Usability” compares usability performance in the acute care EMR market segment.

Results from Lantheus Medical Imaging Inc.’s first Phase 3 study of flurpiridaz F 18 for myocardial perfusion imaging (MPI) were presented at the International Conference on Nuclear Cardiology and Cardiac CT (ICNC12) in Madrid, Spain. The oral presentation was made by Jamshid Maddahi, M.D., professor of medicine (cardiology) and molecular & medical pharmacology (nuclear medicine), David Geffen School of Medicine at UCLA, in the “Important Clinical Trials and Registries in Nuclear Cardiology” session of ICNC12.


A large-scale, multicenter study has shown that therapeutic hypothermia does not improve survival rates or reduce brain injury in infants and children with out-of-hospital cardiac arrest more than normal temperature control.


Thoratec Corp. announced results from the ROADMAP Study (Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients). For the primary endpoint, a composite of survival and functional improvement, ROADMAP demonstrated a statistically significant benefit of HeartMate II LVAD support relative to optimal medical management in ambulatory New York Heart Association (NYHA) Class IIIB/IV (INTERMACS profile 4-7) heart failure patients. One-year study results were presented during the 35th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT 2015) in Nice, France.

Boston Scientific Corp. is taking a new approach to evaluate the performance of the Vessix Renal Denervation System, initiating a study to isolate the effects of the therapy in patients with high blood pressure.

Sunshine Heart Inc. announced that the U.S. Food and Drug Administration (FDA) has reviewed the company’s submission regarding the pause of the COUNTER HF U.S. pivotal study. The FDA has requested minor protocol changes be submitted in order to receive approval to resume patient enrollment.

There have been several technology advances in PET/CT (positron emission tomography/computed tomography) systems recently introduced by vendors. On the show floors of the 2014 Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting and the 2014 Radiological Society of North America (RSNA) meeting, Philips, Toshiba and GE Healthcare introduced new PET/CT systems.


Subscribe Now